BG
NKTR icon

Bellevue Group’s Nektar Therapeutics NKTR Stock Holding History

Bellevue Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-987
Closed -$33.4K – 169
2022
Q4 		$33.4K Hold
987
– – ﹤0.01% 165
2022
Q3 		$47K Sell
987
-933
-49% -$55.5K ﹤0.01% 168
2022
Q2 		$109K Sell
1,920
-318,640
-99% -$20.1M ﹤0.01% 161
2022
Q1 		$25.9M Buy
320,560
+23,780
+8% +$3.52M 0.3% 88
2021
Q4 		$60.1M Sell
296,780
-9,530
-3% -$2.07M 0.62% 54
2021
Q3 		$82.5M Buy
306,310
+32,883
+12% +$7.91M 0.84% 41
2021
Q2 		$70.4M Buy
273,427
+9,787
+4% +$2.71M 0.69% 49
2021
Q1 		$79.1M Buy
263,640
+5,889
+2% +$1.83M 0.84% 39
2020
Q4 		$65.7M Buy
257,751
+15,594
+6% +$4.03M 0.75% 39
2020
Q3 		$60.3M Buy
242,157
+6,489
+3% +$2.04M 0.83% 36
2020
Q2 		$81.9M Buy
235,668
+3,354
+1% +$1.05M 1.16% 23
2020
Q1 		$62.2M Buy
232,314
+4,514
+2% +$1.4M 1.21% 21
2019
Q4 		$73.8M Buy
227,800
+16,274
+8% +$4.72M 1.17% 26
2019
Q3 		$57.8M Buy
211,526
+36,014
+21% +$13.2M 1.07% 27
2019
Q2 		$93.7M Buy
175,512
+146,844
+512% +$73.6M 1.6% 16
2019
Q1 		$14.4M Buy
28,668
+11,254
+65% +$6.67M 0.8% 42
2018
Q4 		$8.59M Buy
17,414
+13,713
+371% +$8.28M 0.56% 49
2018
Q3 		$3.38M Buy
3,701
+1,401
+61% +$1.2M 0.21% 91
2018
Q2 		$1.69M Sell
2,300
-67
-3% -$77.3K 0.14% 95
2018
Q1 		$3.77M Sell
2,367
-2,613
-52% -$3.37M 0.37% 56
2017
Q4 		$4.46M Sell
4,980
-3,220
-39% -$1.9M 0.47% 51
2017
Q3 		$2.95M Buy
8,200
+5,333
+186% +$1.67M 0.31% 70
2017
Q2 		$841K Sell
2,867
-8,600
-75% -$2.49M 0.1% 110
2017
Q1 		$4.04M Sell
11,467
-933
-8% -$210K 0.54% 53
2016
Q4 		$2.28M Hold
12,400
– – 0.47% 57
2016
Q3 		$3.19M Hold
12,400
– – 0.58% 53
2016
Q2 		$2.65M Sell
12,400
-2,000
-14% -$447K 0.5% 64
2016
Q1 		$2.97M Buy
+14,400
New +$2.77M 0.54% 62

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bellevue Group's NKTR Position: Q1 2023 in Review

Bellevue Group sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 987 shares — an estimated $33.4K sold.

Bellevue Group first reported a position in NKTR in Q1 2016 and held it in 28 quarters. The position peaked at $93.7M in Q2 2019. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • Bellevue Group reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bellevue Group sold 987 Nektar Therapeutics shares in Q1 2023, an estimated $33.4K.
  • Bellevue Group first reported a position in Nektar Therapeutics in Q1 2016 and held it in 28 quarters.
  • Bellevue Group's Nektar Therapeutics position peaked at $93.7M in Q2 2019.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.